Work

Supplementary Figure from Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure from Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

DOI: 10.1158/1078-0432.22482984.v1

Authors: Joanne L. Blum, A. Douglas Laird, Jennifer K. Litton, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Miguel Martin, Henri H. Roché, Kyung-Hun Lee, Annabel Goodwin, Ying Chen, Silvana Lanzalone, Jijumon Chelliserry, Akos Czibere, Julia F. Hopkins, Lee A. Albacker, Lida A. Mina

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361813729

Cites:

Cited by:

Related to: 10